Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Rating of “Buy” from Analysts

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) have been given an average recommendation of “Buy” by the six analysts that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $17.10.

Several equities analysts have issued reports on the company. Cantor Fitzgerald upgraded Roivant Sciences to a “strong-buy” rating in a research report on Tuesday, March 4th. HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Tuesday, February 11th.

Insider Buying and Selling

In other Roivant Sciences news, Director Sciences Ltd. Roivant bought 16,845,010 shares of the stock in a transaction on Monday, January 13th. The stock was purchased at an average price of $20.00 per share, with a total value of $336,900,200.00. Following the acquisition, the director now owns 96,650,341 shares of the company’s stock, valued at approximately $1,933,006,820. The trade was a 21.11 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Eric Venker sold 100,000 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $11.28, for a total value of $1,128,000.00. Following the completion of the transaction, the chief operating officer now owns 732,294 shares in the company, valued at $8,260,276.32. This represents a 12.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 2,439,640 shares of company stock worth $27,451,035 over the last three months. 7.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Roivant Sciences

Hedge funds have recently added to or reduced their stakes in the stock. California State Teachers Retirement System increased its stake in shares of Roivant Sciences by 10.7% in the 4th quarter. California State Teachers Retirement System now owns 391,703 shares of the company’s stock valued at $4,634,000 after acquiring an additional 37,982 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Roivant Sciences during the fourth quarter worth $194,000. Jefferies Financial Group Inc. acquired a new position in shares of Roivant Sciences in the 4th quarter valued at $473,000. GF Fund Management CO. LTD. bought a new position in Roivant Sciences during the fourth quarter worth about $181,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Roivant Sciences by 4.5% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,411,466 shares of the company’s stock valued at $28,528,000 after acquiring an additional 104,288 shares during the period. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Stock Down 1.5 %

Shares of Roivant Sciences stock opened at $10.67 on Wednesday. The stock has a market capitalization of $7.61 billion, a P/E ratio of -71.13 and a beta of 1.26. Roivant Sciences has a 12-month low of $9.96 and a 12-month high of $13.06. The company has a 50-day simple moving average of $10.78 and a 200 day simple moving average of $11.44.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. On average, equities analysts anticipate that Roivant Sciences will post -0.92 earnings per share for the current year.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.